The ACCELERATE trial investigated the effects of the CETP inhibitor evacetrapib on cardiovascular outcomes. It found that while evacetrapib significantly increased HDL-C and decreased LDL-C, it did not reduce the risk of major cardiovascular events compared to placebo. Multivariable analyses showed that the changes in lipids induced by evacetrapib were not significantly associated with cardiovascular outcomes. The trial demonstrates that favorable changes in lipids alone through CETP inhibition are not sufficient to improve clinical outcomes in high-risk patients receiving standard treatment.
24 elisa kits for carcinoma of penis researchElabscience
Carcinoma of penis, also called penile cancer, is a malignant growth found on the skin or in the tissues of the penis. Around 95% of penile cancers are squamous cell carcinomas. Other types of penile cancer such as Merkel cell carcinoma, small cell carcinoma, melanoma and other are generally rare.Symptoms include redness of the penis, rash on the penis, foul smelling discharge from the penis and pain in the penis, etc. More info visit: http://www.elabscience.com
Oral cancer, also known as mouth cancer, is a type of head and neck
cancer and is any cancerous tissue growth located in the oral cavity.
Oral or mouth cancer most commonly involves the tongue. It may also
occur on the floor of the mouth, cheek lining, gingiva (gums), lips, or
palate (roof of the mouth). Oncogenes are activated as a result of
mutation of the DNA. Risk factors that predispose a person to oral
cancer have been identified in epidemiological (epidemiology)
studies.More info visit: http://www.elabscience.com
48 elisa kits for thyroid adenoma researchElabscience
A thyroid adenoma is a benign tumor of the thyroid gland. A thyroid adenoma may be clinically silent ("cold" or "warm" adenoma), or it may be a functional tumor, producing excessive thyroid hormone ("hot" adenoma). In this case, it may result in symptomatic hyperthyroidism, and may be referred to as a toxic thyroid adenoma.More info visit: http://www.elabscience.com
A varicocele is an abnormal enlargement of the pampiniform venous plexus in the scrotum. This plexus of veins drains the testicles. The testicular blood vessels originate in the abdomen and course down through the inguinal canal as part of the spermatic cord on their way to the testis. More info visit: http://www.elabscience.com
Thyroiditis is the inflammation of the thyroid gland. Thyroiditis is generally caused by an attack on the thyroid, resulting in inflammation and damage to the thyroid cells. This disease is often considered a malfunction of the immune system. Common hypothyroid symptoms manifest when thyroid cell damage is slow and chronic, and may include fatigue, weight gain, feeling "fuzzy headed," depression, dry skin, and constipation. More info visit: http://www.elabscience.com
24 elisa kits for carcinoma of penis researchElabscience
Carcinoma of penis, also called penile cancer, is a malignant growth found on the skin or in the tissues of the penis. Around 95% of penile cancers are squamous cell carcinomas. Other types of penile cancer such as Merkel cell carcinoma, small cell carcinoma, melanoma and other are generally rare.Symptoms include redness of the penis, rash on the penis, foul smelling discharge from the penis and pain in the penis, etc. More info visit: http://www.elabscience.com
Oral cancer, also known as mouth cancer, is a type of head and neck
cancer and is any cancerous tissue growth located in the oral cavity.
Oral or mouth cancer most commonly involves the tongue. It may also
occur on the floor of the mouth, cheek lining, gingiva (gums), lips, or
palate (roof of the mouth). Oncogenes are activated as a result of
mutation of the DNA. Risk factors that predispose a person to oral
cancer have been identified in epidemiological (epidemiology)
studies.More info visit: http://www.elabscience.com
48 elisa kits for thyroid adenoma researchElabscience
A thyroid adenoma is a benign tumor of the thyroid gland. A thyroid adenoma may be clinically silent ("cold" or "warm" adenoma), or it may be a functional tumor, producing excessive thyroid hormone ("hot" adenoma). In this case, it may result in symptomatic hyperthyroidism, and may be referred to as a toxic thyroid adenoma.More info visit: http://www.elabscience.com
A varicocele is an abnormal enlargement of the pampiniform venous plexus in the scrotum. This plexus of veins drains the testicles. The testicular blood vessels originate in the abdomen and course down through the inguinal canal as part of the spermatic cord on their way to the testis. More info visit: http://www.elabscience.com
Thyroiditis is the inflammation of the thyroid gland. Thyroiditis is generally caused by an attack on the thyroid, resulting in inflammation and damage to the thyroid cells. This disease is often considered a malfunction of the immune system. Common hypothyroid symptoms manifest when thyroid cell damage is slow and chronic, and may include fatigue, weight gain, feeling "fuzzy headed," depression, dry skin, and constipation. More info visit: http://www.elabscience.com
01 elisa kits for malignant ascites researchElabscience
Ascites is a gastroenterological term for an accumulation of fluid in
the peritoneal cavity that exceeds 25 mL. Malignant ascites refers to
ascites caused by metastatic cancer. Patients with ascites generally
will complain of progressive abdominal heaviness and pressure as well
as shortness of breath due to mechanical impingement on the
diaphragm.More info visit: http://www.elabscience.com
Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV). HIV/AIDS has had a great impact on society, both as an illness and as a source of discrimination. More info visit: http://www.elabscience.com
Poster demonstrating the results from the development/verification project for the quantitation of all- trans retinol and alpha tocopherol in human serum.
Validation of an Automated Glutamate Dehydrogenase Enzyme Activity Assay in S...Covance
AACC 2019 -- Hepatotoxicity is an ongoing focus for drug development. Drug-induced liver injury (DILI) figures prominently in the termination of candidates for new drug applications to the FDA and other regulatory authorities. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are accepted as the gold standard for identifying liver injury. However, glutamate dehydrogenase (GLDH) is also being recognized as a valuable biomarker for the detection of DILI. Previous studies have established a strong correlation between GLDH and ALT levels in serum. Moreover, ALT and AST are also found in muscle and other non-hepatic tissues, limiting their utility in detecting DILI in subjects with muscle impairments; thus, GLDH can serve as a useful biomarker that confers greater specificity to the liver. Recently, pharmaceutical companies are requesting GLDH in their clinical trial protocols. In response, Covance has validated the Randox GLDH enzyme activity assay in serum and EDTA plasma.
Measurement of Symmetric Dimethylarginine by LC-MS/MS for the Evaluation of R...Covance
AACC 2019 -- Symmetric and asymmetric dimethylarginine (SDMA and ADMA) are metabolites of the post-translational modification of arginine residues in histones. SDMA is produced by all body tissues and is cleared almost exclusively by the kidneys, making it an attractive biomarker for the evaluation of renal function. In this study, the development of an LC-MS/MS method for the measurement of SDMA is described and its performance reviewed against traditional renal markers in individuals with microalbuminuria or abnormal thyroid function.
14 elisa kits for pheochromocytoma researchElabscience
A pheochromocytoma or phaeochromocytoma (PCC) is a neuroendocrine tumor of the medulla of the adrenal glands, or extra-adrenal chromaffin tissue that failed to involute after birth, that secretes high amounts of catecholamines, mostlynorepinephrine, plus epinephrine to a lesser extent. Up to 25% of pheochromocytomas may be familial.More info visit: http://www.elabscience.com
Kribiolisa ELISA kits for drug monitoring of therapeutic drugs like Adalimumab, Trastuzumab, Atezolizumab, Eculizumab, Ranibizumab. Sensitive assays for drug monitoring and immunogenicity. CE marked.
Elisa kits for children zinc deficiency in children researchElabscience
Children Zinc deficiency,also called Zinc deficiency in children, is defined either qualitatively as insufficient zinc to meet the needs of the body and thereby causing clinical manifestations, or quantitatively as a serum zinc level below the normal range; however, serum zinc is not a reliable biomarker for zinc status in humans, as a decrease in serum concentration is only detectable after long-term or severe depletion.Zinc deficiency results from reduced dietary intake, inadequate absorption, increased loss, or increased use. The most common cause is reduced dietary intake.More info visit:
http://www.elabscience.com
Meningiomas are a diverse set of tumors arising from the meninges, the membranous layers surrounding the central nervous system. Many meningiomas produce no symptoms throughout a person's life, and if discovered, require no treatment other than periodic observation. The causes of meningiomas are not well understood. Most cases are sporadic, appearing randomly, while some are familial.More info visit: http://www.elabscience.com
11 elisa kits for trophoblastic tumor malignant researchElabscience
Tumors differentiated from embryonic trophoblast cells are called
trophoblastic tumor, such as hydatidiform mole, invasive hydatidiform
mole and choriocarcinoma, etc. Invasive hydatidiform mole and
choriocarcinoma are malignant trophoblastic tumor. Common symptoms
include vaginal bleeding, hemoptysis, abdominal pain and abdominal
mass.More info visit: http://www.elabscience.com
15.elisa kits for premature ovarian failure and no response of ovarian syndro...Elabscience
Premature ovarian failure (POF), also known as premature ovarian insufficiency (POI), orprimary ovarian insufficiency is the loss of function of the ovaries before age 40. No response to ovarian syndrome refers to lacking of response to pituitary gonadotropin of women with follicles in ovarian tissue.More info visit: http://www.elabscience.com
19 elisa kits for spinal tumor researchElabscience
Spinal tumors are neoplasms located in the spinal cord. Pain is the most common symptom at presentation. The symptoms seen are due to spinal nerve compression and weakening of the vertebral structure. Other symptoms of spinal cord compression include lower extremity weakness, sensory loss, numbness in hands and legs and rapid onset paralysis.More info visit: http://www.elabscience.com
Poster demonstrating the results from the development/verification project for the quantitation of pyridoxal 5-phosphate and 4-pyridoxic acid in human plasma.
32 elisa kits for cervical cancer researchElabscience
Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Early on, typically no symptoms are seen. Later symptoms may include abnormal vaginal bleeding, pelvic pain, or pain during sexual intercourse. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer.More info visit: http://www.elabscience.com
Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Often, symptoms include poor coordination, stiff muscles, weak muscles, and tremors. There may be problems with sensation, vision, hearing, swallowing, and speaking. Cerebral palsy is caused by abnormal development or damage to the parts of the brain that control movement, balance, and posture. More info visit: http://www.elabscience.com
Регистры сердечно-сосудистых и других неинфекционных заболеваний: значение в ...cardiodrug
Регистры сердечно-сосудистых и других неинфекционных заболеваний: значение в оценке качества лечебно-профилактической помощи в условиях практического здравоохранения
01 elisa kits for malignant ascites researchElabscience
Ascites is a gastroenterological term for an accumulation of fluid in
the peritoneal cavity that exceeds 25 mL. Malignant ascites refers to
ascites caused by metastatic cancer. Patients with ascites generally
will complain of progressive abdominal heaviness and pressure as well
as shortness of breath due to mechanical impingement on the
diaphragm.More info visit: http://www.elabscience.com
Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV). HIV/AIDS has had a great impact on society, both as an illness and as a source of discrimination. More info visit: http://www.elabscience.com
Poster demonstrating the results from the development/verification project for the quantitation of all- trans retinol and alpha tocopherol in human serum.
Validation of an Automated Glutamate Dehydrogenase Enzyme Activity Assay in S...Covance
AACC 2019 -- Hepatotoxicity is an ongoing focus for drug development. Drug-induced liver injury (DILI) figures prominently in the termination of candidates for new drug applications to the FDA and other regulatory authorities. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are accepted as the gold standard for identifying liver injury. However, glutamate dehydrogenase (GLDH) is also being recognized as a valuable biomarker for the detection of DILI. Previous studies have established a strong correlation between GLDH and ALT levels in serum. Moreover, ALT and AST are also found in muscle and other non-hepatic tissues, limiting their utility in detecting DILI in subjects with muscle impairments; thus, GLDH can serve as a useful biomarker that confers greater specificity to the liver. Recently, pharmaceutical companies are requesting GLDH in their clinical trial protocols. In response, Covance has validated the Randox GLDH enzyme activity assay in serum and EDTA plasma.
Measurement of Symmetric Dimethylarginine by LC-MS/MS for the Evaluation of R...Covance
AACC 2019 -- Symmetric and asymmetric dimethylarginine (SDMA and ADMA) are metabolites of the post-translational modification of arginine residues in histones. SDMA is produced by all body tissues and is cleared almost exclusively by the kidneys, making it an attractive biomarker for the evaluation of renal function. In this study, the development of an LC-MS/MS method for the measurement of SDMA is described and its performance reviewed against traditional renal markers in individuals with microalbuminuria or abnormal thyroid function.
14 elisa kits for pheochromocytoma researchElabscience
A pheochromocytoma or phaeochromocytoma (PCC) is a neuroendocrine tumor of the medulla of the adrenal glands, or extra-adrenal chromaffin tissue that failed to involute after birth, that secretes high amounts of catecholamines, mostlynorepinephrine, plus epinephrine to a lesser extent. Up to 25% of pheochromocytomas may be familial.More info visit: http://www.elabscience.com
Kribiolisa ELISA kits for drug monitoring of therapeutic drugs like Adalimumab, Trastuzumab, Atezolizumab, Eculizumab, Ranibizumab. Sensitive assays for drug monitoring and immunogenicity. CE marked.
Elisa kits for children zinc deficiency in children researchElabscience
Children Zinc deficiency,also called Zinc deficiency in children, is defined either qualitatively as insufficient zinc to meet the needs of the body and thereby causing clinical manifestations, or quantitatively as a serum zinc level below the normal range; however, serum zinc is not a reliable biomarker for zinc status in humans, as a decrease in serum concentration is only detectable after long-term or severe depletion.Zinc deficiency results from reduced dietary intake, inadequate absorption, increased loss, or increased use. The most common cause is reduced dietary intake.More info visit:
http://www.elabscience.com
Meningiomas are a diverse set of tumors arising from the meninges, the membranous layers surrounding the central nervous system. Many meningiomas produce no symptoms throughout a person's life, and if discovered, require no treatment other than periodic observation. The causes of meningiomas are not well understood. Most cases are sporadic, appearing randomly, while some are familial.More info visit: http://www.elabscience.com
11 elisa kits for trophoblastic tumor malignant researchElabscience
Tumors differentiated from embryonic trophoblast cells are called
trophoblastic tumor, such as hydatidiform mole, invasive hydatidiform
mole and choriocarcinoma, etc. Invasive hydatidiform mole and
choriocarcinoma are malignant trophoblastic tumor. Common symptoms
include vaginal bleeding, hemoptysis, abdominal pain and abdominal
mass.More info visit: http://www.elabscience.com
15.elisa kits for premature ovarian failure and no response of ovarian syndro...Elabscience
Premature ovarian failure (POF), also known as premature ovarian insufficiency (POI), orprimary ovarian insufficiency is the loss of function of the ovaries before age 40. No response to ovarian syndrome refers to lacking of response to pituitary gonadotropin of women with follicles in ovarian tissue.More info visit: http://www.elabscience.com
19 elisa kits for spinal tumor researchElabscience
Spinal tumors are neoplasms located in the spinal cord. Pain is the most common symptom at presentation. The symptoms seen are due to spinal nerve compression and weakening of the vertebral structure. Other symptoms of spinal cord compression include lower extremity weakness, sensory loss, numbness in hands and legs and rapid onset paralysis.More info visit: http://www.elabscience.com
Poster demonstrating the results from the development/verification project for the quantitation of pyridoxal 5-phosphate and 4-pyridoxic acid in human plasma.
32 elisa kits for cervical cancer researchElabscience
Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Early on, typically no symptoms are seen. Later symptoms may include abnormal vaginal bleeding, pelvic pain, or pain during sexual intercourse. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer.More info visit: http://www.elabscience.com
Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Often, symptoms include poor coordination, stiff muscles, weak muscles, and tremors. There may be problems with sensation, vision, hearing, swallowing, and speaking. Cerebral palsy is caused by abnormal development or damage to the parts of the brain that control movement, balance, and posture. More info visit: http://www.elabscience.com
Регистры сердечно-сосудистых и других неинфекционных заболеваний: значение в ...cardiodrug
Регистры сердечно-сосудистых и других неинфекционных заболеваний: значение в оценке качества лечебно-профилактической помощи в условиях практического здравоохранения
ЭФФЕКТИВНОСТЬ ПРИМЕНЕНИЯ ПРЕПАРАТА ВЕНАРУС В ЛЕЧЕНИИ БОЛЬНЫХ С ПОСТТРОМБОТИЧЕ...OBL-Pharm
Репринт: Ангиология и сосудистая хирургия. Том 20 №4/2014
СОНЬКИН И.Н., ШАЙДАКОВ Е.В., КРЫЛОВ Д.В.,
БУЛАТОВ В.Л., РЕМИЗОВ А.С., РЕЗВАНЦЕВ М.В.
Отделение сосудистой хирургии, Негосударственное учреждение здравоохранения Дорожная клиническая
больница ОАО «РЖД»,
Научно-исследовательский институт экспериментальной медицины Северо-Западного отделения РАН,
Кафедра общественного здоровья и экономики военного здравоохранения, Военно-медицинская академия
им. С.М. Кирова Министерства обороны РФ, Санкт-Петербург, Россия
ЭФФЕКТИВНОСТЬ ПРИМЕНЕНИЯ ПРЕПАРАТА ВЕНАРУС В ЛЕЧЕНИИ БОЛЬНЫХ
С ПОСТТРОМБОТИЧЕСКОЙ БОЛЕЗНЬЮ НИЖНИХ КОНЕЧНОСТЕЙ
В представленной статье изучена эффективность препарата Венарус в комплексном лечении пациентов с посттромботической болезнью. В открытое многоцентровое ретроспективное сравнительное исследование включены 110 больных, разделенных на 2 группы. В первую группу (основную) включен 51 пациент с посттромботическим синдромом, которым проводилось комплексное консервативное лечение с применением флеботоника Венарус. Во вторую (контрольную) группу вошли 59 больных с посттромботическим синдромом, которым проводилось аналогичное консервативное лечение, но без применения
флеботоников.
Доказано, что включение препарата Венарус в комплексное лечение больных с посттромботическим синдромом статистически значимо повышает психологическую и социальную активность и улучшает качество жизни пациентов. В течение стандартного срока применения (2 месяца) Венарус нивелирует субъективные симптомы и некоторые объективные симптомы (по шкале Villalta) посттромботического синдрома. Через два месяца применени
Диагностические исследования в стоматологии необходимы для постановки правильного диагноза и составления корректного плана лечения. Современный подход в дентальной практике исключает методы поставки диагноза «на глаз».
Best of ASCO Metastatic Non-Small Cell Lung CancerH. Jack West
Dr. Jack West's presentation on highlights in advanced non-small cell lung cancer from ASCO 2014, focusing on new agents ramucirumab and necitumumab for broad NSCLC populations, crizotinib and ceritinib for ALK-positive NSCLC, EGFR inhibitor-options of afatinib and bevacizumab added to erlotinib for first line treatment of EGFR mutation-positive NSCLC, and AZD9291 or CO1686 for EGFR mutation-positive patients with acquired resistance.
Hypertension is a major concern & dreaded complication. It is known as the silent killer and responsible for a large number of cardiovascular morbidity and mortality. There are many antihypertensive drugs . Calcium channel blockers were the oldest one and widely used in the management. Azeldipine is the recent addition to this.
Statins are highly effective LDL-c lowering agents that actually reduce clinical cardiovascular events. The 2013 ACC/AHA guidelines on the management of blood cholesterol recommend high-intensity statin therapy in individuals with high cardiovascular risk as assessed by the 10-year atherosclerotic cardiovascular disease risk calculator. However, a significant number of individuals do not tolerate or respond adequately to statins, and continue to have residual risk in spite of high intensity statin therapy.
There are some exciting developments in the field of lipidology. This decade has been labeled “The PCSK9 decade”. A new class of monoclonal antibodies directed against the PCSK9 glycoproteins appears very promising in further lowering LDL cholesterol and thereby cardiovascular risk. Evolocumab and alirucomab are novel PCSK9 inhibitors that can be given subcutaneously once or twice in a month, and have the potential to reduce LDL-cholesterol to very low levels without any major adverse effects.
Other classes of drugs like Apo-B antisense oligonucleotides (mipomersen), CETP inhibitors (especially anacetrapib), microsomal transfer protein inhibitors (lomitapide) also hold some promise. The future of lipid lowering therapy looks reassuring with these new developments.
Shashikiran Umakanth presented this at the Egyptian Association of Endocrinology, Diabetes & Atherosclerosis (EAEDA) 2014 conference at Alexandria, Egypt. This conference was help in association with Endocrine Society, USA and the European Association for the Study of Diabetes (EASD).
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Couples presenting to the infertility clinic- Do they really have infertility...
Esc.lincoff.accelerate.2016
1. AMLAML
Lipid Levels andLipid Levels and CardiovascularCardiovascular Outcome withOutcome with
Cholesteryl Ester Transfer ProteinCholesteryl Ester Transfer Protein (CETP)(CETP) Inhibition byInhibition by
Evacetrapib in the ACCELERATE TrialEvacetrapib in the ACCELERATE Trial
A.A. Michael Lincoff, M.D.Michael Lincoff, M.D.
for thefor the ACCELERATE TrialACCELERATE Trial InvestigatorsInvestigators
Director, C5ResearchDirector, C5Research
(Cleveland Clinic Coordinating Center for Clinical Research)(Cleveland Clinic Coordinating Center for Clinical Research)
Vice Chairman of Cardiovascular MedicineVice Chairman of Cardiovascular Medicine
Professor of MedicineProfessor of Medicine
Late Breaking Clinical Trials –Late Breaking Clinical Trials – ESC Congress 2016,ESC Congress 2016, RomeRome
ACCELERATE was sponsored by Eli Lilly andACCELERATE was sponsored by Eli Lilly and CompanyCompany
3. AMLAML
Speaker Disclosure – A. Michael Lincoff, MDSpeaker Disclosure – A. Michael Lincoff, MD
Relationships withRelationships with IndustryIndustry
Research Funding:Research Funding:
AstraZeneca, CSL Behring, Eli Lilly, Esperion, Pfizer, RocheAstraZeneca, CSL Behring, Eli Lilly, Esperion, Pfizer, Roche
Consultant:Consultant:
Abbott, Amgen, Sarepta, SermonixAbbott, Amgen, Sarepta, Sermonix
Supervisory – C5Research Director:Supervisory – C5Research Director:
Amgen, Atricure, Cardiovascular Systems, Centocor, Covidien, EdwardsAmgen, Atricure, Cardiovascular Systems, Centocor, Covidien, Edwards
Lifesciences, Early Sense, Ethicon, Janssen, Juventas, MedicinesLifesciences, Early Sense, Ethicon, Janssen, Juventas, Medicines
Company, Medtronic, Novartis, Orexigen, Stemedica, TakedaCompany, Medtronic, Novartis, Orexigen, Stemedica, Takeda
4. AMLAML
ACCELERATE TrialACCELERATE Trial
Background and RationaleBackground and Rationale
·· Despite widespread use of statins, many patients continue toDespite widespread use of statins, many patients continue to
experience cardiovascular events.experience cardiovascular events.
·· Considerable efforts have focused on protective effects of HDL as aConsiderable efforts have focused on protective effects of HDL as a
potential therapeutic approach.potential therapeutic approach.
·· Animal and genetic studies suggest that CETP deficiency isAnimal and genetic studies suggest that CETP deficiency is
cardioprotectivecardioprotective
·· Prior trials of CETP inhibitors demonstrated adverse outcomes withPrior trials of CETP inhibitors demonstrated adverse outcomes with
torcetrapib and futility withtorcetrapib and futility with dalcetrapibdalcetrapib
·· Evacetrapib is a potent CETP inhibitor with favorable effects on HDL-C,Evacetrapib is a potent CETP inhibitor with favorable effects on HDL-C,
LDL-C,LDL-C, Lp(aLp(a) and cholesterol efflux in phase 2.) and cholesterol efflux in phase 2.
5. AMLAML
ACCELERATE – Trial DesignACCELERATE – Trial Design
Evacetrapib 130 mgEvacetrapib 130 mg PlaceboPlacebo
1:11:1
RandomizationRandomization
• Event driven - Primary endpoint in 1670 patients (CV death, MI, stroke,
coronary revascularization or hospitalization for unstable angina)
• 84% power to detect a 13.5% reduction in the primary endpoint
• Terminated October 2015 for futility - median 26 months on study drug
(IQR 23-29 months)
High Risk Vascular Disease – 12,092 PatientsHigh Risk Vascular Disease – 12,092 Patients
•• ACS 30-365 daysACS 30-365 days
•• Diabetes with CADDiabetes with CAD
•• Peripheral arterial diseasePeripheral arterial disease
•• CerebrovascularCerebrovascular diseasedisease
LDL-C at target or on maximum tolerated statinLDL-C at target or on maximum tolerated statin
6. AMLAML
Placebo
(n=6054)
Evacetrapib
(n=6038)
Index diagnosis
Acute coronary syndrome 31% 30%
Mean months from event 5.7 5.5
Cerebrovascular atherosclerotic disease 12% 12%
Peripheral arterial disease 14% 14%
Diabetes with coronary artery disease 64% 65%
Statin use 98% 97%
High intensity statin use 46% 46%
ACCELERATE TrialACCELERATE Trial
Enrollment Diagnosis and Statin UseEnrollment Diagnosis and Statin Use
14. AMLAML
Why did favorable changes in HDL-C and LDL-CWhy did favorable changes in HDL-C and LDL-C
induced by CETP inhibition with evacetrapib fail toinduced by CETP inhibition with evacetrapib fail to
improve clinical outcome?improve clinical outcome?
ACCELERATE TrialACCELERATE Trial
§§ Were favorable effects on LDL-C offset byWere favorable effects on LDL-C offset by
unfavorable effects on HDL-C, or vice versa, inunfavorable effects on HDL-C, or vice versa, in
individual patients?individual patients?
§§ Were LDL-C reductions reflective of changes inWere LDL-C reductions reflective of changes in
atherogenic lipoproteins?atherogenic lipoproteins?
§§ Were there other potential adverse effects?Were there other potential adverse effects?
15. AMLAML
Change in HDL-C vs Change in LDL-CChange in HDL-C vs Change in LDL-C
ACCELERATE TrialACCELERATE Trial
r = 0.18
p < 0.001
Placebo r = -0.20
p < 0.001
Evacetrapib
17. AMLAML
Change in Apo-B vs Change in LDL-CChange in Apo-B vs Change in LDL-C
ACCELERATE TrialACCELERATE Trial
r = 0.86
p < 0.001
Placebo
r = 0.85
p < 0.001
Evacetrapib
18. AMLAML
Changes in hs-CRP and Blood Pressure by Month 3Changes in hs-CRP and Blood Pressure by Month 3
ACCELERATE TrialACCELERATE Trial
Placebo
(n=6054)
Evacetrapib
(n=6038)
P-
Value
hs-CRP
mg/L 1.54 1.64
Change from baseline 0 +0.08 <0.001
SBP
mm Hg 131 132
Change from baseline 0 1.2 <0.001
19. AMLAML
hs-CRP – Cumulative Frequency Distributionhs-CRP – Cumulative Frequency Distribution
ACCELERATE TrialACCELERATE Trial
3 Months3 Months 12 Months12 Months
20. AMLAML
Blood Pressure – Cumulative Frequency DistributionBlood Pressure – Cumulative Frequency Distribution
Time-Weighted Change in Systolic BPTime-Weighted Change in Systolic BP
ACCELERATE TrialACCELERATE Trial
22. AMLAML
Multivariable Model of Primary EndpointMultivariable Model of Primary Endpoint
(Apo B substituted for LDL-C)(Apo B substituted for LDL-C)
ACCELERATE TrialACCELERATE Trial
Parameter Baseline
Relative (%) Change from
Baseline
HR (95% CI) P-value HR (95% CI) P-value
Apo-B
(per 10 mg/dl)
1.05 (1.03, 1.08) <0.001 1.02 (0.99, 1.04) 0.16
HDL-C
(per 10 mg/dl)
0.97 (0.93, 1.02) 0.32 1.00 (0.99, 1.01) 0.83
SBP
(per 5 mmHg)
1.03 (1.01, 1.05) <0.001 1.02 (0.99, 1.04) 0.09
* Models adjusted for age, diabetes, hypertension, ACS, CHF, renal impairment and
cerebrovascular atherosclerosis
N = 11,398, # events = 1304N = 11,398, # events = 1304
23. AMLAML
Parameter Baseline
Relative (%) Change from
Baseline
HR (95% CI) P-value HR (95% CI) P-value
LDL-C
(per 10 mg/dl)
1.03 (1.01, 1.06) 0.004 1.01 (0.99, 1.03) 0.37
HDL-C
(per 10 mg/dl)
0.97 (0.91, 1.02) 0.25 1.00 (0.99, 1.01) 0.61
SBP
(per 5 mmHg)
1.03 (1.01, 1.05) 0.006 1.02 (0.99, 1.05) † 0.08
Log hs-CRP 1.16 (1.09, 1.23) <0.001 1.08 (0.99, 1.16) † 0.06
Multivariable Model of Primary EndpointMultivariable Model of Primary Endpoint
(including hs-CRP)(including hs-CRP)
ACCELERATE TrialACCELERATE Trial
* Model adjusted for covariates
† Absolute changes are used for SBP and hs-CRP
N = 8115, # events = 941N = 8115, # events = 941
24. AMLAML
Parameter Baseline
Relative (%) Change from
Baseline
HR (95% CI) P-value HR (95% CI) P-value
LDL-C
(per 10 mg/dl)
1.04 (1.01, 1.07) 0.008 1.02 (0.99, 1.05) 0.26
HDL-C
(per 10 mg/dl)
0.94 (0.88, 1.01) 0.12 1.00 (0.99, 1.01) 0.84
SBP
(per 5 mmHg)
1.03 (1.00, 1.06) 0.02 1.03 (1.00, 1.06) † 0.05
Log hs-CRP 1.18 (1.10, 1.28) <0.001 1.11 (1.01, 1.21) † 0.03
Multivariable Model of Primary EndpointMultivariable Model of Primary Endpoint
Sensitivity Analysis – no change in statin dose and compliantSensitivity Analysis – no change in statin dose and compliant
ACCELERATE TrialACCELERATE Trial
* Model adjusted for covariates
† Absolute changes are used for SBP and hs-CRP
N = 6214, # events = 645N = 6214, # events = 645
25. AMLAML
ACCELERATE TrialACCELERATE Trial
Lipids and Outcome with EvacetrapibLipids and Outcome with Evacetrapib
§§ Evacetrapib treatment for ~2 years did not reduce CV events,Evacetrapib treatment for ~2 years did not reduce CV events,
despite decreasing LDL-C and increasing HDL-Cdespite decreasing LDL-C and increasing HDL-C
§§ Ischemic events were associated withIschemic events were associated with baselinebaseline LDL-C and apo-B,LDL-C and apo-B,
consistent with epidemiologic dataconsistent with epidemiologic data
•• bbutut changeschanges in these lipoproteins by CETP inhibition werein these lipoproteins by CETP inhibition were notnot
correlated with outcomecorrelated with outcome
•• rreasons for lack of association between outcome and changeseasons for lack of association between outcome and changes
in LDL-C and HDL-C remain unclearin LDL-C and HDL-C remain unclear
•• highlights difficulties with even respected surrogates such ashighlights difficulties with even respected surrogates such as
LDL-C to assess therapies with different mechanismsLDL-C to assess therapies with different mechanisms
§§ Inflammatory (CRP) and blood pressure effects of CETP inhibitionInflammatory (CRP) and blood pressure effects of CETP inhibition
with evacetrapib appear to attenuate any potential benefitwith evacetrapib appear to attenuate any potential benefit